安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AMGN 安进

盘后交易 06-16 17:05:42 EDT

347.84

-2.69

-0.77%

盘后347.84

+0.000.00%

16:59 EDT

最高353.66	最低345.87	成交量345.32万
今开352.00	昨收350.53	日振幅2.22%
总市值1,873亿	流通市值1,868亿	总股本5.38亿
成交额12.04亿	换手率0.64%	流通股本5.37亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AMGN","market":"US","secType":"STK","nameCN":"安进","latestPrice":347.84,"timestamp":1781640000000,"preClose":350.53,"halted":0,"volume":3453217,"hourTrading":{"tag":"盘后","latestPrice":347.84,"preClose":347.84,"latestTime":"16:59 EDT","volume":166094,"amount":57774153.5694,"timestamp":1781643560568,"change":0,"changeRate":0,"amplitude":0.011557},"delay":0,"changeRate":-0.007674093515533615,"floatShares":536994627,"shares":538480671,"eps":14.368346,"marketStatus":"盘后交易","change":-2.69,"latestTime":"06-16 17:05:42 EDT","open":352,"high":353.6585,"low":345.87,"amount":1204097504.82271,"amplitude":0.022219,"askPrice":349.99,"askSize":100,"bidPrice":346.01,"bidSize":2,"shortable":3,"etf":0,"ttmEps":14.368346,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1781654400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":423288000000,"exchange":"NASDAQ","adjPreClose":350.53,"dividendRate":0.027771,"preHourTrading":{"tag":"盘前","latestPrice":352.5,"preClose":350.53,"latestTime":"09:28 EDT","volume":70215,"amount":24612853.64325,"timestamp":1781616486204,"change":1.97,"changeRate":0.00562,"amplitude":0.010384},"postHourTrading":{"tag":"盘后","latestPrice":347.84,"preClose":347.84,"latestTime":"16:59 EDT","volume":166094,"amount":57774153.5694,"timestamp":1781643560568,"change":0,"changeRate":0,"amplitude":0.011557},"volumeRatio":0.947781,"impliedVol":0.2617,"impliedVolPercentile":0.3904},"requestUrl":"/m/hq/s/AMGN","defaultTab":"news","newsList":[{"id":"2643223425","title":"和铂医药-B(02142)诉安进专利侵权胜诉获赔约2020.37万美元 最高可追偿三倍赔偿金","url":"https://stock-news.laohu8.com/highlight/detail?id=2643223425","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643223425?lang=zh_cn&edition=full","pubTime":"2026-06-15 08:32","pubTimestamp":1781483572,"startTime":"0","endTime":"0","summary":"经过2026年6月8日开始的陪审团庭审后，陪审团认定：安进侵犯了Grosveld专利，该侵权行为属于故意侵权， Grosveld专利有效，及 Harbour Antibodies有权获得约2020.37万美元的损害赔偿——即公司请求的全额赔偿。故意侵权的认定使Harbour Antibodies有权请求法院提高损害赔偿金额，可能包括最高三倍的损害赔偿。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4599","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU2112291526.USD","LU0122379950.USD","LU2242646821.SGD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU2468319806.SGD","IE0009355771.USD","LU2242652126.USD","IE00BJJMRZ35.SGD","LU1061106388.HKD","LU2089984988.USD","LU0058720904.USD","LU1023059063.AUD","LU0868494617.USD","LU0889565916.HKD","BK1161","AMGN","BK4581","LU0320765992.SGD","BK4566","IE00B2B36J28.USD","IE0002141913.USD","BK4585","02142","LU1983299246.USD","BK4588","LU1571399168.USD","BK4534","LU1057294990.SGD","BK4533","SG9999001440.SGD","BK1574","BK1583","BK4139","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101472667","title":"EMA药委会就Tavneos强化肝功能监测要求达成共识 将向医疗专业人员发布直接沟通文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1101472667","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101472667?lang=zh_cn&edition=full","pubTime":"2026-06-12 20:07","pubTimestamp":1781266039,"startTime":"0","endTime":"0","summary":"欧洲药品管理局（EMA）的药物警戒风险评估委员会（PRAC）已达成一致，将就Tavneos（avacopan）的强化肝功能监测要求，向医疗专业人员发布一份直接沟通文件。\n此举旨在进一步强调并确保对使用该药物的患者进行适当的肝脏安全性监测。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","LU0320765992.SGD","BK4566","LU0889565916.HKD","LU0289739699.SGD","LU2242646821.SGD","LU0058720904.USD","BK4534","BK4533","LU0122379950.USD","LU2242652126.USD","BK4139","IE00B2B36J28.USD","LU2468319806.SGD","BK4581","BK4588","BK4585","IE00B4R5TH58.HKD","LU1571399168.USD","LU2112291526.USD","LU1023059063.AUD","AMGN","BK4599","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU1061106388.HKD","IE0002141913.USD","IE0009355771.USD","LU1983299246.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","LU2089984988.USD","SG9999001440.SGD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642259474","title":"安进(AMGN.US)聘请杜克临床研究所独立复核 力保明星药Tavneos免于退市","url":"https://stock-news.laohu8.com/highlight/detail?id=2642259474","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642259474?lang=zh_cn&edition=full","pubTime":"2026-06-12 11:25","pubTimestamp":1781234700,"startTime":"0","endTime":"0","summary":"信中提到，杜克临床研究所自今年2月起，已启动一项“独立且完全设盲的重新裁定”，针对支持Tavneos获批的ADVOCATE后期临床研究的主要终点结果进行复核。面对重重质疑，安进在信中强调，公司认为Tavneos的获益大于风险，将药物撤市“不符合患者的最佳利益”。杜克临床研究所则对此拒绝置评。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"安进(AMGN.US)聘请杜克临床研究所独立复核 力保明星药Tavneos免于退市","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0289739699.SGD","BK4581","LU1983299246.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","BK4139","LU1571399168.USD","LU2242652126.USD","LU0889565916.HKD","IE00B2B36J28.USD","BK4599","LU2089984988.USD","LU2242646821.SGD","BK4585","IE0009355771.USD","LU1057294990.SGD","BK4588","BK4566","LU1061106388.HKD","LU0868494617.USD","LU2112291526.USD","LU2468319806.SGD","IE00BJT1NW94.SGD","LU0122379950.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU1023059063.AUD","BK4533","BK4534","SG9999001440.SGD","AMGN","LU0058720904.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125954811","title":"异动解读｜安进盘中上涨3.22%，欧盟批准其小细胞肺癌新药Imdylltra持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1125954811","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125954811?lang=zh_cn&edition=full","pubTime":"2026-06-11 22:33","pubTimestamp":1781188394,"startTime":"0","endTime":"0","summary":"6月11日，安进盘中上涨3.22%，报348.62美元/股，成交额1.65亿美元。消息面上，欧盟委员会近日正式批准安进公司的Imdylltra®，用于治疗广泛期小细胞肺癌，为患者提供了新的治疗选择。该产品获批进一步拓展了安进在肿瘤领域的商业化布局，有望为公司带来新的营收增长点，市场情绪持续受此提振。安进所在的生物科技行业中，个股表现分化，其中Insmed涨3.01%，吉利德科学涨2.86%，艾伯维公司跌0.4%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153045404","title":"安进于美国糖尿病协会第86届科学会议上展示其心脏代谢产品组合新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1153045404","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153045404?lang=zh_cn&edition=full","pubTime":"2026-06-08 04:46","pubTimestamp":1780865173,"startTime":"0","endTime":"0","summary":"安进公司在美国糖尿病协会第86届科学会议上，公布了其心脏代谢产品系列的最新研究数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","LU0889565916.HKD","IE0002141913.USD","IE0009355771.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU1571399168.USD","SG9999001440.SGD","LU0320765992.SGD","LU0058720904.USD","IE00BFTCPJ56.SGD","BK4566","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU0122379950.USD","BK4534","LU2242646821.SGD","BK4139","LU1023059063.AUD","LU2242652126.USD","LU2089984988.USD","LU1983299246.USD","BK4533","LU1057294990.SGD","LU0289739699.SGD","LU2112291526.USD","AMGN","LU0109394709.USD","LU1061106388.HKD","IE00B4R5TH58.HKD","BK4585","BK4581","BK4588","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157311090","title":"异动解读｜安进盘中上涨3.02%，欧盟批准其小细胞肺癌新药Imdylltra持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1157311090","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157311090?lang=zh_cn&edition=full","pubTime":"2026-06-06 00:44","pubTimestamp":1780677891,"startTime":"0","endTime":"0","summary":"6月6日，安进盘中上涨3.02%，报356.02美元/股，成交额4.3亿美元。消息面上，欧盟委员会近日正式批准安进公司的Imdylltra®，用于治疗广泛期小细胞肺癌，为患者提供了新的治疗选择。该产品获批进一步拓展了安进在肿瘤领域的商业化布局，有望为公司带来新的营收增长点，市场情绪持续受此提振。安进所在的生物科技行业中，个股整体表现偏暖，其中Argenx SE涨5.75%，福泰制药涨2.46%，艾伯维公司涨2.29%，吉利德科学涨1.71%，再生元制药公司涨1.65%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191021067","title":"异动解读｜安进盘中上涨3.01%，欧盟批准其小细胞肺癌新药Imdylltra","url":"https://stock-news.laohu8.com/highlight/detail?id=1191021067","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191021067?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:06","pubTimestamp":1780581992,"startTime":"0","endTime":"0","summary":"6月4日，安进盘中上涨3.01%，报346.541美元/股，成交额1.03亿美元。消息面上，欧盟委员会近日正式批准安进公司的Imdylltra®，用于治疗广泛期小细胞肺癌，为患者提供了新的治疗选择。该产品获批进一步拓展了安进在肿瘤领域的商业化布局，有望为公司带来新的营收增长点，市场情绪受此提振。安进所在的生物科技行业中，个股整体表现偏暖，其中Abivax S.A.涨7.58%，福泰制药涨3.54%，艾伯维公司涨2.19%，再生元制药公司涨1.12%，吉利德科学涨0.6%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162739507","title":"异动解读｜安进盘中上涨3.06%，欧盟批准其小细胞肺癌新药Imdylltra","url":"https://stock-news.laohu8.com/highlight/detail?id=1162739507","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162739507?lang=zh_cn&edition=full","pubTime":"2026-06-04 03:57","pubTimestamp":1780516622,"startTime":"0","endTime":"0","summary":"6月4日，安进盘中上涨3.06%，报338.31美元/股，成交额4.89亿美元。消息面上，欧盟委员会近日正式批准安进公司的Imdylltra®，用于治疗广泛期小细胞肺癌，为患者提供了新的治疗选择。该产品获批拓展了安进在肿瘤领域的商业化布局，有望为公司带来新的营收增长点，市场情绪受此提振。安进所在的生物科技行业中，个股整体表现偏暖，其中Abivax S.A.涨24.17%，再生元制药公司涨2.58%，吉利德科学涨1.06%，艾伯维公司涨1.04%，福泰制药涨0.76%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110834574","title":"欧盟委员会批准安进Imdylltra®用于广泛期小细胞肺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1110834574","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110834574?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:00","pubTimestamp":1780344012,"startTime":"0","endTime":"0","summary":"欧盟委员会已正式批准安进公司的Imdylltra®，用于治疗广泛期小细胞肺癌。这一决定为患者提供了一种新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","IE00BJJMRZ35.SGD","LU1061106388.HKD","BK4533","BK4585","LU1571399168.USD","LU2089984988.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","IE00B4R5TH58.HKD","LU1023059063.AUD","IE00BJT1NW94.SGD","LU0109394709.USD","BK4534","LU0320765992.SGD","BK4581","LU2242646821.SGD","LU1983299246.USD","IE0002141913.USD","BK4588","AMGN","BK4566","LU2468319806.SGD","IE00B2B36J28.USD","BK4139","BK4599","LU2112291526.USD","LU0868494617.USD","LU0889565916.HKD","LU0058720904.USD","IE0009355771.USD","LU1057294990.SGD","LU2242652126.USD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169515854","title":"异动解读｜安进盘中下跌3.02%，报326.615美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169515854","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169515854?lang=zh_cn&edition=full","pubTime":"2026-06-01 23:18","pubTimestamp":1780327135,"startTime":"0","endTime":"0","summary":"6月1日，安进盘中下跌3.02%，报326.615美元/股，成交额1.7亿美元。安进所在的生物科技行业中，个股表现分化，其中BridgeBio Pharma跌0.25%，Revolution Medicines涨2.08%，艾伯维公司跌2.27%，Hyperliquid Strategies涨9.16%，Summit Therapeutics跌6.53%。安进公司成立于1980年，是全球领先的独立生物技术公司之一，专注于发现、开发、制造和交付创新药物，致力于对抗高度未满足医疗需求领域的疾病。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637548398","title":"罕见病明星药因死亡病例或遭美国撤市，安进中国回应：国内尚未商业化，未有患者接受治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2637548398","media":"澎湃新闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637548398?lang=zh_cn&edition=full","pubTime":"2026-05-22 13:21","pubTimestamp":1779427260,"startTime":"0","endTime":"0","summary":"近期，因肝损伤相关死亡病例，美国安进公司的罕见病治疗药物阿伐可泮胶囊（中文商品名：特福尼，英文商品名：Tavneos）被美国监管部门提议撤销上市批准，而该药此前也在中国市场获批。5月22日，安进中国向澎湃新闻记者表示，在中国，阿伐可泮胶囊已于2024年11月获得中国国家药品监督管理局（NMPA）批准，但尚未商业化上市，截至目前中国尚无患者接受特福尼治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605223746529631.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605223746529631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4566","SG9999001440.SGD","BK4599","LU1983299246.USD","IE0009355771.USD","LU0868494617.USD","BK4139","LU0058720904.USD","LU1057294990.SGD","LU2242646821.SGD","LU2468319806.SGD","BK4534","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4581","LU0320765992.SGD","LU0289739699.SGD","IE0002141913.USD","LU1061106388.HKD","LU2089984988.USD","BK4533","LU1023059063.AUD","LU0109394709.USD","LU0889565916.HKD","LU1571399168.USD","AMGN","LU2242652126.USD","LU0122379950.USD","BK4588","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU2112291526.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635303779","title":"Piper Sandler下调安进目标价至427美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635303779","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635303779?lang=zh_cn&edition=full","pubTime":"2026-05-15 11:17","pubTimestamp":1778815022,"startTime":"0","endTime":"0","summary":"Piper Sandler将安进的目标价从432美元下调至427美元，维持“增持”评级。(格隆汇)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260515/32227062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["UUP","UDN","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146480534","title":"安进追加3亿美元美国制造投资，过去一年总投资额逼近20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146480534","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146480534?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:01","pubTimestamp":1777899680,"startTime":"0","endTime":"0","summary":"生物技术巨头安进公司宣布将向其美国制造业务追加3亿美元投资，这一举措使其在过去12个月内对美国本土生产设施的总投入达到近20亿美元。\n此次最新投资延续了安进强化国内供应链的战略布局，彰显了公司对提升生物制药产能的长期承诺。近20亿美元的资本注入将用于现代化生产设备升级和新技术平台部署，以支持创新疗法的规模化生产。\n作为全球生物制药领域的领导者，安进持续加大在美国的制造投入，这不仅有助于保障关键药品的稳定供应，也将为当地创造更多高技能就业岗位。公司表示，这项投资将进一步提升其应对未来医疗需求的能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999001440.SGD","BK4581","LU2242646821.SGD","BK4534","BK4139","LU1571399168.USD","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU0122379950.USD","IE00BJT1NW94.SGD","LU0109394709.USD","LU2468319806.SGD","LU0320765992.SGD","LU0889565916.HKD","BK4566","LU0868494617.USD","LU2089984988.USD","LU2112291526.USD","IE00B2B36J28.USD","BK4599","IE0002141913.USD","IE0009355771.USD","LU2242652126.USD","BK4533","AMGN","LU1061106388.HKD","BK4585","LU1983299246.USD","LU1023059063.AUD","IE00B4R5TH58.HKD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107055076","title":"安进提交Cbe-30文件修订肝毒性警示语 为Tavneos相关血管炎病例提供更详细信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1107055076","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107055076?lang=zh_cn&edition=full","pubTime":"2026-05-01 04:03","pubTimestamp":1777579396,"startTime":"0","endTime":"0","summary":"生物制药巨头安进公司近日向监管机构提交了Cbe-30类别文件，对其产品标签中的肝毒性警告内容进行了重要修订。此次更新特别针对与Tavneos相关的血管炎病例信息披露进行了强化，在原有警示基础上补充了更具临床参考价值的病例数据。这一调整体现了安进对药物安全监测的持续重视，旨在帮助医生更准确地评估用药风险收益比。公司表示将继续密切监测Tavneos在真实世界应用中的安全性表现，确保患者用药安全。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","LU0889565916.HKD","IE0002141913.USD","IE0009355771.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU1571399168.USD","SG9999001440.SGD","LU0320765992.SGD","LU0058720904.USD","IE00BFTCPJ56.SGD","BK4566","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU0122379950.USD","BK4534","LU2242646821.SGD","BK4139","LU1023059063.AUD","LU2242652126.USD","LU2089984988.USD","LU1983299246.USD","BK4533","LU1057294990.SGD","LU0289739699.SGD","LU2112291526.USD","AMGN","LU0109394709.USD","LU1061106388.HKD","IE00B4R5TH58.HKD","BK4585","BK4581","BK4588","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112223752","title":"安进计划与FDA展开沟通 坚信Tavneos展现疗效及良好获益-风险特征","url":"https://stock-news.laohu8.com/highlight/detail?id=1112223752","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112223752?lang=zh_cn&edition=full","pubTime":"2026-05-01 04:02","pubTimestamp":1777579369,"startTime":"0","endTime":"0","summary":"生物技术巨头安进公司表示，计划与美国食品药品监督管理局（FDA）进行积极沟通。该公司持续坚信，其药物Tavneos在临床应用中展现出显著疗效，并具备良好的获益-风险特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0122379950.USD","LU2089984988.USD","LU0289739699.SGD","IE00BJJMRZ35.SGD","LU2112291526.USD","BK4581","LU2242646821.SGD","LU2468319806.SGD","BK4599","IE0009355771.USD","BK4534","LU0868494617.USD","IE0002141913.USD","LU1057294990.SGD","LU0889565916.HKD","LU0109394709.USD","AMGN","LU1983299246.USD","BK4566","LU0320765992.SGD","LU1061106388.HKD","LU1571399168.USD","SG9999001440.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU2242652126.USD","IE00BJT1NW94.SGD","BK4533","IE00B4R5TH58.HKD","BK4139","LU1023059063.AUD","BK4588","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193530232","title":"FDA明确：Tavneos将继续在市场销售，直至申请人主动撤市或局长强制要求","url":"https://stock-news.laohu8.com/highlight/detail?id=1193530232","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193530232?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:44","pubTimestamp":1777337053,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）近日发布声明，针对药物Tavneos的市场地位作出明确表态。该药物将继续在市场上合法销售，其去留将取决于两种情形：一是由申请方（即制药公司）自行决定将其撤市；二是由FDA局长行使职权，强制要求其退出市场。此举为Tavneos的未来提供了明确的监管框架。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","BK4566","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0109394709.USD","BK4139","BK4534","IE00BJJMRZ35.SGD","LU0122379950.USD","BK4588","AMGN","BK4599","LU1057294990.SGD","LU1571399168.USD","LU0889565916.HKD","IE0009355771.USD","LU2468319806.SGD","LU2242646821.SGD","IE0002141913.USD","IE00B4R5TH58.HKD","LU2242652126.USD","LU2089984988.USD","LU2112291526.USD","LU0868494617.USD","BK4585","LU1061106388.HKD","LU0320765992.SGD","BK4581","SG9999001440.SGD","LU0058720904.USD","LU1023059063.AUD","LU1983299246.USD","LU0289739699.SGD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182507856","title":"财报前瞻｜安进本季度营收预计增6.60%，机构观点看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1182507856","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182507856?lang=zh_cn&edition=full","pubTime":"2026-04-23 08:14","pubTimestamp":1776903287,"startTime":"0","endTime":"0","summary":"安进将于2026年04月30日发布最新季度财报，市场普遍预期营收与盈利延续温和增长，关注管线催化对收入结构与利润率的影响。依据当前一致预期，本季度安进营收预计为85.89亿美元，同比增长6.60%；调整后每股收益预计为4.76美元，同比增长10.79%；息税前利润预计为36.30亿美元，同比增长9.07%；市场未提供本季度毛利率与净利率或净利润的预测数据，相关指标暂不展示。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜安进本季度营收预计增6.60%，机构观点看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627415479","title":"百济神州年营收382亿：净利14.6亿 安进与Baker是核心股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2627415479","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627415479?lang=zh_cn&edition=full","pubTime":"2026-04-15 09:52","pubTimestamp":1776217938,"startTime":"0","endTime":"0","summary":"百济神州有限公司（公司代码：688235 公司简称：百济神州）日前发布截至2025年12月31日的财报。财报显示，百济神州2025年营收为382.25亿，较上年同期的272亿增长40.46%；","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260415/6391184353468399959612189.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260415/6391184353468399959612189.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33283/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["688235","ONC","AMGN","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627498112","title":"港股异动 | 再鼎医药(09688)涨超3% 近日与安进达成全球临床合作 Zoci正处于全球注册性临床III期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2627498112","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627498112?lang=zh_cn&edition=full","pubTime":"2026-04-14 09:46","pubTimestamp":1776131184,"startTime":"0","endTime":"0","summary":"消息面上，近日，再鼎医药官微宣布，公司与安进公司达成一项全球临床研究合作，旨在评估再鼎医药处于临床阶段的靶向delta样配体3的抗体药物偶联物zocilurtatug pelitecan联合安进IMDELLTRA，一款靶向DLL3的双特异性T细胞衔接器疗法，用于治疗广泛期小细胞肺癌患者。作为该合作协议的一部分，安进将申办一项全球1b期研究，评估zoci联合IMDELLTRA在ES-SCLC患者中的安全性和有效性。再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4533","LU2242646821.SGD","LU2112291526.USD","LU1983299246.USD","IE0002141913.USD","BK4526","LU2468319806.SGD","LU1571399168.USD","LU2488822045.USD","AMGN","BK4588","IE00BJT1NW94.SGD","BK4548","BK1161","IE00BFTCPJ56.SGD","BK4531","IE00B4R5TH58.HKD","BK4534","BK1574","LU0109394709.USD","LU0289739699.SGD","LU0868494617.USD","LU2242652126.USD","ZLAB","BK4134","LU1061106388.HKD","IE0009355771.USD","SG9999001440.SGD","VXUS","III","LU1023059063.AUD","BK1588","LU0058720904.USD","BK4581","09688","BK4139","BK4566","LU1057294990.SGD","IE00BJJMRZ35.SGD","LU0122379950.USD","BK4585","LU2089984988.USD","LU0889565916.HKD","LU0320765992.SGD","BK4599","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626198497","title":"安进肺癌药物他拉妥单抗获中国批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626198497","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626198497?lang=zh_cn&edition=full","pubTime":"2026-04-10 16:40","pubTimestamp":1775810400,"startTime":"0","endTime":"0","summary":"安进研发合作伙伴及商业化合作方贝达药业周五在微信平台宣布，安进的肺癌药物他拉妥单抗已获中国国家药品监督管理局批准。该药属于安进管线中的双特异性抗体药物，其作用机制是同时结合癌细胞与免疫细胞，使人体免疫系统能够杀伤癌细胞。　　安进与在港上市的贝达药业均未就该药物在中国市场的上市时间及定价回应置评请求。　　部分华尔街分析师表示，他拉妥单抗有望为安进带来每年超 20 亿美元的销售收入。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-10/doc-inhtzamv8056323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","SG9999001440.SGD","BK4581","LU2242646821.SGD","BK4534","BK4139","LU1571399168.USD","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU0122379950.USD","IE00BJT1NW94.SGD","LU0109394709.USD","LU2468319806.SGD","LU0320765992.SGD","LU0889565916.HKD","BK4566","LU0868494617.USD","LU2089984988.USD","LU2112291526.USD","IE00B2B36J28.USD","BK4599","IE0002141913.USD","IE0009355771.USD","LU2242652126.USD","BK4533","AMGN","LU1061106388.HKD","BK4585","LU1983299246.USD","LU1023059063.AUD","IE00B4R5TH58.HKD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amgen.com","stockEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.0742},{"period":"3month","weight":-0.0294},{"period":"6month","weight":0.0752},{"period":"1year","weight":0.1874},{"period":"ytd","weight":0.0709}],"compareEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.1253},{"period":"6month","weight":0.1243},{"period":"1year","weight":0.2644},{"period":"ytd","weight":0.1069}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Amgen Inc是一家生物技术公司。该公司从事发现、开发、生产和提供治疗最棘手疾病的药物。该公司专注于医疗需求尚未得到满足的领域，并利用专业知识努力寻求改善人们生活的解决方案。该公司在人类治疗领域开展业务。该公司的营销产品组合包括EPOGEN（阿法依泊汀）、Aranesp（阿法达贝泊汀）、Parsabiv（etelcalcetide）、Neulasta（培非格司亭）；KANJINTI（曲妥珠单抗）、Otezla、BLINCYTO（blinatumomab）、ACTIMMUNE（干扰素γ-1b）、Neulasta（培非格司亭）、Sensipar/Mimpara（西那卡塞）、Prolia（地舒单抗）、ENBREL、QUINSAIR（左氧氟沙星）、Repatha（依洛尤单抗）等。该公司在美国和加拿大销售肿瘤坏死因子阻断剂ENBREL。该公司在全球许多国家销售抑制磷酸二酯酶4的小分子药物Otezla。该公司在全球许多国家销售前蛋白转化酶枯草溶菌素/kexin 9型 (PCSK9) 抑制剂Repatha。","yearOnYearQuotes":[{"month":1,"riseRate":0.651163,"avgChangeRate":0.034336},{"month":2,"riseRate":0.488372,"avgChangeRate":0.00202},{"month":3,"riseRate":0.511628,"avgChangeRate":0.016602},{"month":4,"riseRate":0.44186,"avgChangeRate":-0.003156},{"month":5,"riseRate":0.511628,"avgChangeRate":0.022981},{"month":6,"riseRate":0.511628,"avgChangeRate":0.004734},{"month":7,"riseRate":0.767442,"avgChangeRate":0.052562},{"month":8,"riseRate":0.604651,"avgChangeRate":0.004451},{"month":9,"riseRate":0.511628,"avgChangeRate":0.002296},{"month":10,"riseRate":0.534884,"avgChangeRate":0.021538},{"month":11,"riseRate":0.627907,"avgChangeRate":0.022348},{"month":12,"riseRate":0.627907,"avgChangeRate":0.045446}],"exchange":"NASDAQ","name":"安进","nameEN":"Amgen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安进,AMGN,安进股票,安进股票老虎,安进股票老虎国际,安进行情,安进股票行情,安进股价,安进股市,安进股票价格,安进股票交易,安进股票购买,安进股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}